Synta's lung cancer drug ganetespib wins fast-track status from FDA

09/16/2013 | Pharmaceutical Business Review Online

The FDA granted fast-track designation to Synta Pharmaceuticals' ganetespib, which is being developed as a therapy for metastatic nonsmall-cell lung adenocarcinoma. The drug, a heat shock protein 90 inhibitor, is in a midstage and late-stage trial program.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA